Search

Displaying results 3531 - 3540 of 8974 in total
  1. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    It is approved in more than 60 countries worldwide but not in the US. … Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid.

    Mixtures: ETRAL - TR
  2. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Trypan blue free acid

    go.drugbank.com/drugs/DB09158
    Approved

    This is done to aid in visualization before creating the continuous curvilinear capsulorhexis. … Trypan blue is a diazo dye used in ophthalmic cataract surgery to stain the anterior capsule in the presence of a mature cataract.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Piritramide

    go.drugbank.com/drugs/DB12492
    ApprovedWithdrawn

    Piritramide is under investigation for the treatment of Colon Cancer and Minimal Residual Disease. … Piritramide has been investigated for the supportive care of Pain, Postoperative and Postoperative Nausea and Vomiting.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10321
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION
  6. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.

  7. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    [A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this … It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity.

  8. Drug

    BLX-883

    go.drugbank.com/drugs/DB05904
    Investigational

    BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. … Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.

  9. Drug

    Mebendazole

    go.drugbank.com/drugs/DB00643
    ApprovedInvestigationalVet approved

    A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

    Products: MEBENDAZOL TABLETAS POR 100 MG
  10. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.